Integra LifeSciences Holdings Corporation (NASDAQ:IART) Director Donald E. Morel, Jr. purchased 2,500 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The shares were purchased at an average cost of $49.29 per share, with a total value of $123,225.00. Following the completion of the acquisition, the director now owns 29,612 shares in the company, valued at approximately $1,459,575.48. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of Integra LifeSciences Holdings Corporation (IART) traded up 0.35% on Friday, reaching $49.08. The company’s stock had a trading volume of 325,548 shares. The stock has a 50 day moving average of $53.52 and a 200-day moving average of $46.63. The firm has a market cap of $3.83 billion, a price-to-earnings ratio of 59.85 and a beta of 0.73. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million for the quarter, compared to analysts’ expectations of $283.58 million. During the same period last year, the firm earned $0.40 earnings per share. The company’s revenue for the quarter was up 13.2% compared to the same quarter last year. On average, analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/04/insider-buying-integra-lifesciences-holdings-corporation-iart-director-acquires-2500-shares-of-stock.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Manhattan Co. bought a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter worth about $117,000. LS Investment Advisors LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 90.7% in the first quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock worth $102,000 after buying an additional 1,147 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Integra LifeSciences Holdings Corporation by 223.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock worth $107,000 after buying an additional 1,751 shares during the period. Turner Investments LLC bought a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter worth about $126,000. Finally, Elkfork Partners LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 121.2% in the first quarter. Elkfork Partners LLC now owns 3,212 shares of the life sciences company’s stock worth $135,000 after buying an additional 1,760 shares during the period. 89.56% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts recently weighed in on IART shares. Jefferies Group LLC lifted their price target on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 price objective on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Monday, May 15th. Cantor Fitzgerald set a $65.00 price objective on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Wednesday, July 26th. UBS AG reaffirmed a “buy” rating and issued a $60.00 price objective (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a report on Friday, June 9th. Finally, ValuEngine cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $52.63.
Integra LifeSciences Holdings Corporation Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
